CLO20-035: Real-World Minimal Residual Disease (MRD) Assessment and Trends Using clonoSEQ in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma

Authors:
Audrey Demaree Adaptive Biotechnologies Corp., Seattle, WA

Search for other papers by Audrey Demaree in
Current site
Google Scholar
PubMed Close
 PharmD
,
Anthony Hewitt Adaptive Biotechnologies Corp., Seattle, WA

Search for other papers by Anthony Hewitt in
Current site
Google Scholar
PubMed Close
 MBS
,
Ben Eckert Adaptive Biotechnologies Corp., Seattle, WA

Search for other papers by Ben Eckert in
Current site
Google Scholar
PubMed Close
 MS
, and
Lik Wee Lee Adaptive Biotechnologies Corp., Seattle, WA

Search for other papers by Lik Wee Lee in
Current site
Google Scholar
PubMed Close
 PhD
Volume/Issue:
Volume 18: Issue 3.5
Online Publication Date:
20 Mar 2020
DOI:
https://doi.org/10.6004/jnccn.2019.7476
Restricted access

Corresponding Author: Audrey Demaree, PharmD
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
Copyright:
Copyright © 2020 by the National Comprehensive Cancer Network 2020
Article Category:
Abstract
Print Publication Date:
20 Mar 2020
Online Publication Date:
20 Mar 2020

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2324 502 44
PDF Downloads 1565 0 0
EPUB Downloads 0 0 0